[1S-[1α,2α(Z),3α,4α]]-6-[3-[4-[(propylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo-[2.2.1]hept-2-yl]-4-hexenoic acid | 130776-05-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: [1S-[1α,2α(Z),3α,4α]]-6-[3-[4-[(propylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo-[2.2.1]hept-2-yl]-4-hexenoic acid
• 英文别名: (Z)-6-[(1S,2R,3S,4R)-3-[4-(propylcarbamoyl)-1,3-oxazol-2-yl]-7-oxabicyclo[2.2.1]heptan-2-yl]hex-4-enoic acid
• CAS: 130776-05-5
• 化学式: C₁₉H₂₆N₂O₅
• 分子量: 362.426
• InChiKey: DIJPQWIYPNMHJC-PHJKGNKCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  26
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• 7-Oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
  申请人：E.R. SQUIBB & SONS, INC.

  公开号：EP0374952A2

  公开（公告）日：1990-06-27

  7-Oxabicycloheptane substituted prostaglandin analogs which are thromboxane A2 (TxA2) receptor antagonists or combined thromboxane A2 receptor antagonists/thromboxane synthase inhibitors useful, for example, in treating thrombotic and vasospastic disease have the structural formula wherein m is 1, 2 or 3; n is 0, 1, 2, 3 or 4; Z is -(CH2)2- or -CH=CH-, with the proviso when Z is -CH = CH-, n is 1, 2, 3 or 4; R is C02H, CO2lower alkyl, CH2OH, CO2alkali metal, CONHSOR3, CONHR3a or -CH2-5-tetrazolyl, X is 0, S or NH; and where R1, R2, R3 and R3a are as defined herein.

  7-氧杂双环庚烷取代的前列腺素类似物是血栓素 A2（TxA2）受体拮抗剂或血栓素 A2 受体拮抗剂/血栓素合成酶联合抑制剂，可用于治疗血栓性疾病和血管痉挛性疾病等，其结构式为 其中 m 是 1、2 或 3；n 是 0、1、2、3 或 4；Z 是-(CH2)2- 或-CH=CH-，但当 Z 是-CH=CH-时，n 是 1、2、3 或 4；R 是 C02H、 lower 烷基、 OH、CO2 碱金属、CONHSOR3、CONHR3a 或- -5-四唑基，X 是 0、S 或 NH；其中 R1、R2、R3 和 R3a 如本文所定义。
• Use of a thromboxane A2 receptor antagonist for the manufacture of a medicament for the treatment of ulcerative gastrointestinal conditions
  申请人：E.R. SQUIBB & SONS, INC.

  公开号：EP0448274A2

  公开（公告）日：1991-09-25

  A method is provided for protecting against and/or treating ulcerative gastrointestinal conditions, including anti-inflammatory drug-induced gastrointestinal ulcers, using a thromboxane A₂ receptor antagonist. In addition, a combination is provided which includes a thromboxane A₂ receptor antagonist and an anti-inflammatory agent which combination may be used to treat inflammatory conditions, such as arthritis, while inhibiting formation of and/or treating gastrointestinal ulcers.

  本发明提供了一种使用血栓素 A₂受体拮抗剂防止和/或治疗胃肠道溃疡病的方法，包括抗炎药物诱发的胃肠道溃疡。此外，还提供了一种组合物，其中包括血栓素 A₂受体拮抗剂和一种消炎药，该组合物可用于治疗关节炎等炎症，同时抑制胃肠道溃疡的形成和/或治疗胃肠道溃疡。
• COMPOSITIONS AND METHODS OF TREATING SYSTEMIC SCLEROSIS OR PULMONARY ARTERIAL HYPERTENSION
  申请人：Cumberland Pharmaceuticals, Inc.

  公开号：EP3804717A1

  公开（公告）日：2021-04-14

  The present invention is directed to methods of treating, preventing, and/or ameliorating systemic sclerosis or pulmonary arterial hypertension, by administration of a therapeutically effective amount of ifetroban, or a pharmaceutically acceptable salt thereof.

  本发明涉及通过服用治疗有效量的伊伐曲班或其药学上可接受的盐来治疗、预防和/或改善系统性硬化症或肺动脉高压的方法。
• METHODS OF TREATING HEPATORENAL SYNDROME AND HEPATIC ENCEPHALOPATHY WITH THROMBOXANE-A2 RECEPTOR ANTAGONISTS
  申请人：Pavliv Leo

  公开号：US20130197044A1

  公开（公告）日：2013-08-01

  The present invention is directed to methods of treating hepatorenal syndrome by administration of a therapeutically effective amount of a thromboxane A 2 receptor antagonist to a patient in need thereof. The present invention is also directed to methods of treating hepatic encephalopathy and cerebral edema by administration of a therapeutically effective amount of a thromboxane A 2 receptor antagonist to a patient in need thereof.
• Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists
  申请人：Cumberland Emerging Technologies, Inc.

  公开号：US20150297571A1

  公开（公告）日：2015-10-22

  The present invention is directed to methods of treating hepatorenal syndrome by administration of a therapeutically effective amount of a thromboxane A 2 receptor antagonist to a patient in need thereof. The present invention is also directed to methods of treating hepatic encephalopathy and cerebral edema by administration of a therapeutically effective amount of a thromboxane A 2 receptor antagonist to a patient in need thereof.